Abstracts

Citation

Le CN, Britto P, Brummel S, Hoffman RM, Flynn PM, Taha TE, Coletti A, Fowler MG, Klingman KL, McIntyre JA, Li JZ, Currier JS. HIV-1 viral rebound and safety outcomes of postpartum treatment interruption in women. Presented at: CROI 2018; 2020 Mar 08.

Citation

Hoffman RM, Warshaw M, Amico KR, Pilotto JH, Masheto G, Achalapong J, Machado ES, Chokephaibulkit K, Duarte G, Coletti A, Browning R, Chakhtoura N, Klingman K, and Currier JS, for the PROMISE 1077HS team. Predictors of virologic failure in postpartum women on ART in PROMISE 1077HS. Presented at: CROI 2018; 2020 Mar 07.

Citation

Meyers T, Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Hovind L, Sise T, Teppler H, Dittmer S, Fairlie L, Hesseling AC, Cotton MF. Phase I/II study of a raltegravir-containing regimen in HIV-infected children with TB. Presented at: CROI 2018; 2018 Mar 05.

Citation

MacBrayne CE, Rutstein R, Yogev R, Wiznia A, Fairlie L, Graham B, Alvero C, Moye J, Townley E, Crauwels H, Woot de Trixhe X, Tambuyzer L, Vanveggel S, Opsomer M, Kiser JJ. Etravirine pharmacokinetics in treatmentexperienced HIV-infected children =12 mos to 6 yrs. Presented at: CROI 2018; 2018 Mar 07.

Citation

Zuend CF, Tobin N, Birse K, Noël-Romas L, Vera T, Kotyrba L, Mutch S, Abo M, McCorrister S, Westmacott G, Aldrovandi GM, Burgener A. Pregnancy associated vaginal proteome alterations linked to HIV acquisition risks. Presented at: CROI 2018; 2020 Mar 07.

Citation

Lameck Chinula, Sean S. Brummel, Lauren Ziemba, Lynda Stranix-Chibanda, Anne Coletti, Chelsea Krotje, Patrick Jean-Philippe, Lee Fairlie, Tichaona Vhembo, Deo Wabwire, Risa M. Hoffman, Paul E. Sax, Jeffrey S. Stringer, Judith S. Currier, Shahin Lockman. Safety and efficacy of DTG vs EFV and TDF vs TAF in pregnancy: IMPAACT 2010 trial. Presented at: CROI 2020; 2020 Mar 11.

Citation

Minda Nikanjam, Lana Tran, Ellen G. Chadwick, Mutsa Bwakura-Dangarembizi, Carolyn Bolton Moore, Pearl Samson, Stephen A Spector, Nahida Chakhtoura, Patrick Jean-Philippe, Lisa Frenkel, Bonnie Zimmer, Alex Benns, Jennifer Libous, Edmund V. Capparelli. Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age. Presented at: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2020; 2020 Sep 28.

Citation

C. Cunningham, E. Capparelli, E. McFarland, P. Muresan, C. Perlowski, E. Smith, R. Hazra, L. Purdue, P. Harding, A. McDermott, J. Mascola, B. Graham. Safety and PK of Potent Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants. Presented at: HIV R4P 2021; 2021 Jan 27.

Citation

E. Brown, L. Stranix-Chibanda, B. Johnston, S. Huang, D. Kacanek, L. Mungate, A. Sango, S. Mambiya, W. Longwe Mwenda, V. Korutaro, S. Nanyunja, P. Kibalama Ssemambo, A. Ssekasi Miwanda, H. Kowo, S. Nelwamondo, H. Spiegel, P. Anderson, B. Chi, K. Lypen. Directly Observed Therapy (DOT) can be Implemented Successfully in Research Settings to Evaluate PrEP PK among Pregnant and Postpartum Adolescents and Young Women in Africa. Presented at: HIV R4P 2021; 2021 Jan 27.

Citation

A Gupta, L Aaron , G Theron, K McCarthy, S Bradford, T Chipato, T Vhembo, L Stranix-Chibanda, C Onyango-Makumbi , G Masheto, N Chakhtoura, P Jean-Phillippe , R Browning , T Sterling, A Weinberg, G Montepiedra, IMPAACT P1078 TB APPRISE Study Team. Risk factors for hepatotoxicity in HIV-infected women receiving isoniazid preventive therapy in pregnancy and postpartum. Presented at: International AIDS Conference.